Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited financial report for the first quarter of 2025, ending on March 31. The report, prepared in accordance with PRC Accounting Standards, assures stakeholders of the truthfulness and accuracy of the financial information, as confirmed by the company’s senior management.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development, manufacturing, and distribution of pharmaceutical products.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $8B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.